Pharmacological prevention of venous thromboembolism in medical patients at risk

American Journal of Cardiovascular Drugs

Volumn 5, Issue 6, 2005, Pages 409-415

  Wolozinsky, Mia ^a   Yavin, Yshai Y ^a   Cohen, Alexander T ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

AGE DISTRIBUTION; ANAMNESIS; BLEEDING; CANCER; CAUSE OF DEATH; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ENTERITIS; HEART DISEASE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL; HUMAN; INFECTION; LUNG EMBOLISM; META ANALYSIS; OBESITY; PHLEBOGRAPHY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; THROMBOPHILIA; ULTRASOUND; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ASPIRIN; BANDAGES; CLINICAL TRIALS; HEPARIN; HUMANS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 27744526024     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200505060-00008     Document Type: Review

References (66)

1. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 709-11
2. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-5
3. Cohen AT, Edmondson RA, Phillips MJ, et al. The changing pattern of venous thromboembolic disease. Haemostasis 1996; 26: 65-71
4. Shojania KG, Duncan BW, McDonald KM, et al, editors. Making health care safer: a critical analysis of patient safety practices [online]. Evidence Report/Technology Assessment No. 43 (Prepared by the University of California at San Francisco-Stanford Evidence-based Practice Center under Contract No. 290-97-0013), AHRQ Publication No. 01-E058, Rockville, MD: Agency for Healthcare Research and Quality, July 2001. Available from URL: http://www.ncbi.nlm.nih. gov/books/bv.fcgi?.rid=hstat1.chapter.59276 [Accessed 2005 Sep 5]
5. Sperry KL, Key CR, Anderson RE. Toward a population-based assessment of death due to pulmonary embolism in New Mexico. Hum Pathol 1990; 21: 159-65
6. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism: Seventh ACCP recommendations. Chest 2004; 126: 338S-400S
7. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism: international consensus statement guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37
8. Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800
9. Leizorovicz A, Cohen AT, Turpie AGG, et al. A randomized placebo controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9
10. Cohen AT, Davidson BL, Gallus AS, et al. Fondaparinux for the prevention of VTE in acutely ill medical patients [abstract]. Blood 2003; 102: 42
11. Anderson FA, Wheeler HB, Goldberg RJ, et al. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 581-5
12. Ageno W, Squizzata A, Ambrosini F, et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002; 87: 746-50
13. Ahmad HA, Geissler A, Maclellan DG. Deep venous thrombosis prophylaxis: are guidelines being followed? ANZ J Surg 2002; 72: 331-4
14. Bergmann JF, Mouly S. Thromboprophylaxis in medical patients: focus on France. Semin Thromb Hemost 2002; 28 Suppl. 3: 51-5
15. Arcelus JI, Candocia S, Traverso CI, et al. Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 1991; 17 Suppl. 3: 313-8
16. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119: 132S-75S
17. Emerson PA, Marks P. Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. BMJ 1977; 1: 18-20
18. Handley AJ. Low-dose heparin after myocardial infarction. Lancet 1972; II: 623-4
19. Warlow C, Beattie AG, Terry G, et al. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973; II: 934-6
20. Belch JJ, Lowe GDO, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 115-7
21. Anderson GM, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J 1950; 39: 697-702
22. Kierkegaard A, Norgren L, Olsson C-G, et al. Incidence of deep vein thrombosis in bedridden non-surgical patients. Acta Med Scand 1987; 222: 409-14
23. Donati MB. Cancer and thrombosis. Haemostasis 1994; 24: 128-31
24. Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 2001; 73: 137-44
25. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72: 43-52
26. Otten HMMB, Prins MH, Smorenburg SM, et al. Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: cancer as a risk factor. Haemostasis 2000; 30 Suppl. 2: 72-6
27. Clarke-Pearson DL, Synan IS, Colemen RE, et al. The natural history of postoperative venous thromboemboli in gynaecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol 1984; 148: 1051-4
28. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89: 640-6
29. Fraisse F, Holzapfel L, Coulaud J-M, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 2000; 161: 1109-14
30. Prescott SM, Richards KL, Tikoff G, et al. Venous thromboembolism in decompensated chronic obstructive pulmonary disease: a prospective study. Am Rev Respir Dis 1981; 123: 32-6
31. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-8
32. Haas S. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002; 28: 577-83
33. Motykie GD, Caprini JA, Arcelus JI, et al. Risk factor assessment in the management of patients with suspected deep vein thrombosis. Int Angiol 2000; 19: 47-51
34. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX Study. Blood Coagul Fibrinolysis 2003; 14: 341-6
35. Sandercock PAG, van den Belt AGM, Lindley RI, et al. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25
36. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119 (1 Suppl.): 108S-21S
37. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 2004; 164: 963-8
38. Samama M-M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients. Arch Intern Med 2000; 160: 3415-20
39. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63
40. Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-73
41. Laffan M, Tuddenham E. Assessing thrombotic risk. BMJ 1998; 317: 520-3
42. Gensini GF, Prisco D, Falciani M, et al. Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost 1997; 23: 55-67
43. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-8
44. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-5
45. Leone G, Sica S, Chiusolo P, et al. Blood cell diseases and thrombosis. Haematologica 2001; 86: 1236-44
46. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-80
47. Daly E, Vessey MP, Painter R, et al. Case-control study of venous thromboembolism in users of hormone replacement therapy [letter]. Lancet 1996; 348: 1027
48. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone replacement therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132: 689-96
49. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66
50. Bates SM. Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 2003; 108: 97-106
51. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-50
52. Cade JF, Andrews JT, Stubbs AE. Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med 1982; 12: 501-4
53. Ibarra-Pérez C, Lau-Cortés E, Colmenero-Zubiate S, et al. Prevalence and prevention of deep vein thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988; 39: 505-13
54. Gårdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996; 347: 1357-61
55. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated heparin or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9
56. Carter CJ, Kelton JG, Hirsh J, et al. The relationship between haemorrhagic and antithrombotic properties of LMWH and heparins. Blood 1982; 59 (6): 1239-45
57. Esquivel CO, Bergqvist D, Bjork C-G, et al. Comparison between commercial heparin, LMWH and pentosan polysulphate on haemostasis and platelets in vivo. Thromb Res 1982; 28: 389-99
58. Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). THE PRIME study group. Haemos-tasis 1996; 26 Suppl. 2: 49-56
59. Kleber F-X, Witt C, Vogel G, et al. A randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease: THE-PRINCE study group. Am Heart J 2003; 145: 614-21
60. Hillbom M, Erilä T, Sotaniemi K, et al. Enoxaparin vs heparin for prevention of deep vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 2002; 106: 84-92
61. Lloyd A, Anderson P, Quinlan DJ, et al. Economic evaluation of prophylaxis of venous thromboembolism in acute medical patients with enoxaparin in the UK [abstract no. 3659]. Blood 2000; 96 (11): 847a
62. Reynolds NA, Perry CM, Scott LJ. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery. Drugs 2004; 64 (14): 1575-96
63. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 Sep 9; 162 (16): 1833-40
64. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235-46
65. Amarigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2003; (3): CD001484
66. Mazzone C, Chiodo Grandi F, Sandercock P, et al. Physical methods for preventing deep vein thrombosis in stroke. Cochrane Database Syst Rev 2004 Oct 18; (4): CD001922